Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Brief, intermittent bouts of moderate- to vigorous-intensity physical activity during daily routines may significantly reduce the risk of type 2 diabetes in adults who do not engage in leisure-time exercise.
The FreeDM2 trial demonstrates that real-time CGM significantly improves HbA1c levels compared to SMBG in adults with type 2 diabetes on basal insulin and modern therapies, with sustained benefits over 32 weeks.
Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.
A study demonstrates that short bursts of vigorous bodyweight exercise reduce postprandial hyperglycemia and glycemic variability in individuals with type 2 diabetes, offering a practical intervention for glucose management.
A retrospective study of 135 pediatric BBS patients reveals high prevalence of obesity (77.6%) and short stature (21.1%), with low rates of hypogonadism, hypothyroidism, and glucose metabolism disorders compared to adult populations.
A large-scale cohort study demonstrates that GLP-1 RAs significantly reduce macrovascular and microvascular complications, including proliferative retinopathy and retinal vein occlusion, in patients with pre-existing diabetic retinopathy.
The CONDOR trial demonstrates brolucizumab’s superiority over panretinal photocoagulation in preserving vision and reducing disease progression in proliferative diabetic retinopathy, offering a potential shift in treatment paradigms.
68Ga-pentixafor PET/CT parameters correlate with clinical success post-adrenalectomy in primary aldosteronism, offering prognostic insights linked to histopathologic subtypes and CXCR4 expression.
A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.
The updated glucose management indicator (uGMI) significantly improves alignment with HbA1c, reducing discordance, particularly in high and low glucose ranges, offering clinicians a more reliable tool for diabetes monitoring.
A study of 1,454 older adults with metabolic syndrome reveals that long-term exposure to air pollutants like black carbon, PM2.5, and NO2 is associated with increased fat mass and decreased lean mass, persisting over three years, particular
A retrospective study reveals that the TSH-FT4 relationship is segmented, not log-linear, with implications for refining thyroid function test interpretation and reference intervals.
Study reveals significant time gaps between fingerstick glucose tests and insulin administration in hospitals, with nearly 30% of cases potentially receiving incorrect insulin doses due to changing glucose levels during delays.
New study reveals uniform distribution of somatostatin and its receptors throughout the intestinal tract in both healthy individuals and type 2 diabetes patients, challenging previous assumptions about its role in diabetes pathophysiology.
A 36-year prospective study demonstrates that cumulative BMI burden from childhood to adulthood significantly elevates risks of metabolic multimorbidity, with distinct life-stage patterns and sex-specific vulnerabilities.
Phase 3a trial in Japan/Taiwan shows cagrilintide-semaglutide combination delivers superior weight loss (18.4%) versus semaglutide alone (11.9%) in adults with overweight/obesity ± type 2 diabetes, with comparable safety profiles dominated
A randomized trial found that a $80 monthly produce prescription did not significantly improve HbA1c levels or reduce healthcare utilization in diabetic patients at risk of food insecurity.
A Greenlandic study shows that Inuit with a specific sucrase-isomaltase gene variant have better glucose regulation on a Western diet compared to non-carriers, suggesting potential new diabetes treatments.
A real-world study validates the 2025 ATA thyroid cancer risk guidelines, showing significant patient reclassification and identifying a new ‘low-intermediate-risk’ group needing tailored management approaches.
A retrospective study of 670 papillary thyroid carcinoma patients validates the 2025 ATA risk stratification system, demonstrating a shift toward higher-risk classifications. The new ‘low-intermediate-risk’ class emerges as a di
Open language-specific specialty feeds and department pages.